Gastric and oesophageal cancer: trials for referral
1482 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Gastric and oesophageal cancer·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 1482 open trials.
Phase 14 sites
RecruitingUnited States
NCT07903415
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pfizer
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingAustralia
NCT07939230
Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults
Peter MacCallum Cancer Centre, Australia
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07938021
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 1/2104 sites
RecruitingBelgium, China, Germany, Spain, France, United Kingdom +4
NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 1/25 sites
RecruitingJapan, United States
NCT07730021
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Astellas Pharma Global Development, Inc.
Pre-treatment window Registry sentence: “Participant has had no prior systemic therapy administered with the exception of systemic therapy completed \> 6 months prior if given as part of multimodal treatment with curative intent for nonmetastatic disease stages.”
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 126 sites
RecruitingSouth Korea, United States
NCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07939204
A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
Tianjin Medical University Cancer Institute and Hospital
Registry updated 16 Nov 2026
Registry record: ClinicalTrials.govPhase 1/250 sites
RecruitingBrazil, Switzerland, Chile, China, Germany, France +6
NCT06469944
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has histologically and/or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic first-line (1L) gastroesophageal adenocarcinoma”
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 19 sites
RecruitingCanada, Spain, Japan, United States
NCT07360314
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 1/254 sites
RecruitingBrazil, Switzerland, Chile, China, Czechia, Germany +10
NCT06780111
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Merck Sharp & Dohme LLC
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingChina
NCT07923214
A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 2/378 sites
RecruitingUnited States
NCT07001748
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 2/32 sites
Not yet recruitingChina
NCT07935369
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
RemeGen Co., Ltd.
Registry updated 13 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3378 sites
RecruitingUnited States
NCT06203600
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT04907643
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingChina
NCT07933471
Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Tsinghua Chang Gung Hospital
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govPhase 23 sites
Not yet recruitingSpain
NCT07788664
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)
Vall d'Hebron Institute of Oncology
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07551362
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Beijing Biotech
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07622940
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Beijing Biotech
Registry updated 12 Nov 2026
Registry record: ClinicalTrials.govPhase 123 sites
Not yet recruitingSpain, France, United Kingdom, Japan, United States
NCT07928258
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Eli Lilly and Company
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 127 sites
RecruitingSpain, Georgia, United States
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06675136
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT06054906
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer
Huashan Hospital
Pre-treatment window Registry sentence: “No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/234 sites
RecruitingBrazil, Switzerland, Chile, China, Czechia, France +6
NCT07405151
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07924111
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection
CSPC Megalith Biopharmaceutical Co.,Ltd.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07581405
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer
University of Illinois Chicago
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07924332
Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Qun Zhao
Pre-treatment window Registry sentence: “No prior anti-cancer therapy (surgery, radiotherapy, chemotherapy, targeted or immunotherapy).”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3136 sites
RecruitingBelgium, China, Czechia, Germany, Spain, France +7
NCT07673887
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06487221
Avutometinib and Defactinib in Diffuse Gastric Cancer
Ryan H. Moy, MD, PhD
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07408609
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- China187 open trials
- United States162 open trials
- South Korea47 open trials
- Spain45 open trials
- Japan43 open trials
- France36 open trials
- Italy36 open trials
- Australia32 open trials
- United Kingdom30 open trials
- Taiwan29 open trials
- Germany26 open trials
- Canada20 open trials
- Netherlands19 open trials
- Brazil15 open trials
- Belgium14 open trials
- Poland14 open trials
- Puerto Rico14 open trials
- Türkiye12 open trials
- Chile10 open trials
- Norway10 open trials
- Singapore9 open trials
- Switzerland8 open trials
- Portugal7 open trials
- Thailand6 open trials
- Czechia5 open trials
- Romania5 open trials
- Argentina5 open trials
- Israel5 open trials
- Georgia4 open trials
- Mexico4 open trials
- India4 open trials
- New Zealand4 open trials
- Austria4 open trials
- Ireland4 open trials
- Hungary3 open trials
- Malaysia3 open trials
- Vietnam3 open trials
- Sweden3 open trials
- Denmark2 open trials
- Hong Kong2 open trials
- Colombia1 open trial
- Finland1 open trial
- Peru1 open trial
- Moldova1 open trial
- Tanzania1 open trial
- Russia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Amsterdam UMC Location University of Amsterdam
Amsterdam, Netherlands
6 trials · 38 publications · ROR
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
35 trials · 88 publications · ROR
First Affiliated Hospital of GuangXi Medical University
Nanning, China
1 trial · 38 publications · ROR
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
11 trials · 44 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma
NCT07939997 · No phase · United States
Source: ClinicalTrials.govNew in the registry
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
NCT07938021 · Phase 2 · China
Source: ClinicalTrials.govNew in the registry
Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults
NCT07939230 · Phase 1 · Australia
Source: ClinicalTrials.govOpened for recruitment
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00 · Phase 1 · Belgium, Germany, Spain, France, Italy, Portugal
Source: EU CTISOpened for recruitment
Shanghai Clinical Cohort - Esophageal Cancer
NCT07312526 · No phase · China
Source: ClinicalTrials.govPaused
A study to investigate the safety and efficacy of ONA-255 in participants with advanced cancer
2025-522233-62-00 · Phase 1/2 · Spain
Source: EU CTISOpened for recruitment
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
NCT07880106 · No phase · China
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
[68Ga]Ga-ABY-025 PET in solid tumors
2022-500448-39-00 · Phase 2 · Sweden
Source: EU CTISClosed for recruitment
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244 · Phase 1/2 · United States
Source: ClinicalTrials.govNew in the registry
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258 · Phase 1 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Meta-analysis
Journal of gastrointestinal cancer · PubMed
Systematic review
Frontiers in oncology · PubMed
Randomised trial
Journal of cancer research and clinical oncology · PubMed
Meta-analysis
Journal of medical Internet research · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 3 Nov 2026
Stopped early53 participants
NCT05075993
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Reason given: \<75% participation
Phase 2Ended 26 Oct 2026
Phase 1/2Ended 16 Oct 2026
Paused15 participants
NCT04908111
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Reason given: Sponsor has decided to permanently close recruitment
No phaseEnded 14 Oct 2026
No phaseEnded 9 Oct 2026
Completed15 participants
NCT06202781
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
No phaseEnded 6 Oct 2026
Completed48 participants
NCT06335966
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
Phase 1/2Ended 1 Oct 2026
Stopped early194 participants
NCT04868877
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Reason given: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.
Phase 2Ended 17 Sept 2026
Phase 2Ended 14 Sept 2026
No phaseEnded 9 Sept 2026
Stopped early22 participants
NCT03482791
Proton Beam Therapy in the Treatment of Esophageal Cancer
Reason given: The study is no longer relevant to have open to ensure insurance approval for this patient population
Phase 2Ended 7 Sept 2026
No phaseEnded 31 Aug 2026
Completed2527 participants
NCT06790355
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Phase 3Ended 28 Aug 2026
Completed1040 participants
NCT05568095
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. · Journal of the National Comprehensive Cancer Network : JNCCN, 2025
Phase 3Ended 15 Aug 2026
Phase 1Ended 7 Aug 2026
Completed16 participants
NCT04522336
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
No phaseEnded 6 Aug 2026
Stopped early9 participants
NCT06549413
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Reason given: \<75% participation
No phaseEnded 1 Aug 2026
No phaseEnded 1 Aug 2026
Completed118 participants
NCT07828314
Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study
Phase 2Ended 31 Jul 2026
Completed87 participants
NCT02572050
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection
Phase 1Ended 31 Jul 2026
Show more
Phase 1/2Ended 31 Jul 2026
Stopped early100 participants
NCT04427449
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
No reason given in the registry.
No phaseEnded 30 Jul 2026
Completed75000 participants
NCT06902337
Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany
Phase 2Ended 27 Jul 2026
Phase 1Ended 22 Jul 2026
Completed77 participants
NCT06131398
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 3Ended 22 Jul 2026
Completed760 participants
NCT04543617
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study. · Annals of oncology : official journal of the European Society for Medical Oncology, 2026
Phase 1Ended 16 Jul 2026
Completed138 participants
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
No phaseEnded 13 Jul 2026
Completed300 participants
NCT07722819
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
No phaseEnded 6 Jul 2026
Completed52 participants
NCT07540169
The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer
Phase 2Ended 6 Jul 2026
Completed51 participants
NCT04354662
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Phase 1/2Ended Jun 2026
Withdrawn before start0 participants
NCT05312372
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Reason given: Strategic development reasons
Phase 3Ended 30 Jun 2026
Completed367 participants
NCT01882933
D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma
Phase 2/3Ended 30 Jun 2026
Completed127 participants
NCT05002127
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
No phaseEnded 30 Jun 2026
Completed465 participants
NCT07705412
Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Phase 1Ended 30 Jun 2026
Completed58 participants
NCT05396300
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer. · Therapeutic advances in medical oncology, 2024
Phase 3Ended 30 Jun 2026
Completed342 participants
NCT04375605
Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ
- Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. · Journal of the National Comprehensive Cancer Network : JNCCN, 2025
- RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. · BMC cancer, 2020
Phase 3Ended 26 Jun 2026
Completed703 participants
NCT04210115
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. · Future oncology (London, England), 2021
Phase 2Ended 25 Jun 2026
Phase 2Ended 20 Jun 2026
Completed21 participants
NCT05941481
Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ
Phase 2Ended 16 Jun 2026
Completed104 participants
2023-503905-12-00
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors
Phase 4Ended 8 Jun 2026
Paused36 participants
NCT02366819
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Reason given: Pending data analysis
No phaseEnded 7 Jun 2026
Stopped early264 participants
NCT07629921
Multimodal Al for Precision Diagnosis of Esophageal Cancer
Reason given: local ethics review
Phase 2Ended 4 Jun 2026
Completed54 participants
NCT04739202
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
Phase 2Ended 2 Jun 2026
Phase 1/2Ended 2 Jun 2026
Completed98 participants
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
No phaseEnded 1 Jun 2026
Completed414 participants
NCT07488624
Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
Phase 1Ended 22 May 2026
Stopped early57 participants
NCT05514717
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Reason given: Development discontinued.
Phase 3Ended 20 May 2026
Stopped early863 participants
NCT04949256
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Reason given: Trial was rendered as cancelled work ongoing in the book of business.
- LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. · Future oncology (London, England), 2024
No phaseEnded 19 May 2026
Completed196 participants
NCT05489757
Quantitative Fluorescence Angiography With ICG for Perfusion Assessment During Surgery
Phase 2Ended 7 May 2026
Phase 2/3Ended 4 May 2026
Completed429 participants
NCT03081143
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
- Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). · BMC cancer, 2023
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. · European journal of cancer (Oxford, England : 1990), 2022
Phase 3Ended 26 Apr 2026
Completed547 participants
NCT05052801
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. · JCO precision oncology, 2025
- Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. · Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024
- Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. · Journal of the National Comprehensive Cancer Network : JNCCN, 2025
Phase 1Ended 23 Apr 2026
Stopped early47 participants
NCT06585488
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Reason given: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.
Phase 2Ended 21 Apr 2026
Completed110 participants
NCT04923932
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Phase 1/2Ended 20 Apr 2026
No phaseEnded 14 Apr 2026
Phase 4Ended 14 Apr 2026
Completed50 participants
NCT07224048
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
Phase 2Ended 25 Mar 2026
Completed189 participants
NCT05515796
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Phase 1Ended 16 Mar 2026
Completed102 participants
NCT05867121
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Phase 4Ended 6 Mar 2026
Completed65 participants
NCT06013098
Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer
Not medical advice. fetched 17 Nov 2026